{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
MiconaHex plus Triz Wipes by Dechra Veterinary Products
(2016)
Source URL:
First approved in 2004
Source:
M014
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2004)
Source URL:
First approved in 2004
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2004)
Source URL:
First approved in 2004
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
ANDA209074
(2024)
Source URL:
First approved in 2004
Source:
21 CFR 355
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2004
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2004
Source:
M017
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103189
(2009)
Source URL:
First approved in 2004
Source:
BLA125070
Source URL:
Class:
CONCEPT
Status:
US Approved Rx
(2022)
Source:
ANDA209085
(2022)
Source URL:
First approved in 2004
Source:
NDA021462
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pemetrexed is a new-generation antifolate, approved for the treatment of mesothelioma and non-small cell lung cancer, currently being evaluated for the treatment of a variety of other solid tumors.
Pemetrexed, is a folate analog metabolic inhibitor that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT) and and to a lesser extent aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life resulting in prolonged drug action in malignant cells.
Status:
US Approved Rx
(2004)
Source:
NDA021468
(2004)
Source URL:
First approved in 2004
Source:
NDA021468
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Lanthanum hydroxide (La(OH)3) is a rare novel earth compound which has so far been fabricated with various morphologies such as nanopowders, nanotubes, nanowires, nanorods and nanobelts from different methods like solvothermal, hydrothermal, sol-gel and template assisted routes. This compound has many attractive applications in gas-exhaust convectors, optical coatings, catalysts, superconductors, hydrogen storage materials and next generation of high dielectric constant gate dielectrics. It is a useful carrier precipitate for a number of ions. It was applied to the collection of traces of aluminum, bismuth, gold, iridium, iron, lead, thallium and titanium in silver metal. It is a predecessor Lanthanum oxide, which has a great interest as catalyst material.
Status:
US Approved Rx
(2004)
Source:
NDA021468
(2004)
Source URL:
First approved in 2004
Source:
NDA021468
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Lanthanum hydroxide (La(OH)3) is a rare novel earth compound which has so far been fabricated with various morphologies such as nanopowders, nanotubes, nanowires, nanorods and nanobelts from different methods like solvothermal, hydrothermal, sol-gel and template assisted routes. This compound has many attractive applications in gas-exhaust convectors, optical coatings, catalysts, superconductors, hydrogen storage materials and next generation of high dielectric constant gate dielectrics. It is a useful carrier precipitate for a number of ions. It was applied to the collection of traces of aluminum, bismuth, gold, iridium, iron, lead, thallium and titanium in silver metal. It is a predecessor Lanthanum oxide, which has a great interest as catalyst material.